How is the bone tumor treatment technology?

With the advancement of surgical, chemotherapy, and radiotherapy treatment methods, the long-term survival rate of patients with malignant bone and soft tissue tumors has improved, but some patients are still not immune to recurrence or metastasis.

About 60% of patients with malignant bone and soft tissue tumors already have micro-metastases at the time of surgery. Surgery, even radical surgery, can only resolve local tumors but not systemic metastases.

Studies have shown that surgery, radiotherapy, and chemotherapy can cure some tumor patients, not because they kill all tumor cells, but because when the bone tumor cell load is significantly reduced, the body's immune function recovers, clears tiny residual lesions or significantly inhibits the proliferation of residual bone tumor cells. This shows that the body's immunity is important for tumor growth and transformation.

The biggest advantage of bone tumor immunotherapy is that it targets tumor cells. Even non-specific killer cells such as natural killer cells are more toxic to tumor cells than normal cells. This is especially valuable for patients whose immune function has been compromised and who need radiotherapy and chemotherapy.

However, since the mechanism of tumor occurrence is not yet fully understood, except for a small number of bone tumors that can easily stimulate the body's immune response, most of them are difficult to stimulate the body's immune response, which brings many difficulties to immunotherapy.

After years of basic and clinical experimental research, bone tumor immunotherapy has made great progress and presented an attractive development prospect. However, due to the complexity of the occurrence and development of bone tumors and the many influencing factors, there are still many problems to be studied and solved.

Bone tumors: http://www..com.cn/zhongliu/ga/gzl.html